PT-141
PT-141 is a synthetic melanocortin receptor agonist studied for MC3R and MC4R receptor binding and CNS-mediated signaling pathway research. Its mechanism of action through central melanocortin pathways distinguishes it from peripheral-acting compounds in laboratory investigation. For research purposes only.
Weekdays before 2PM EST
With Every Batch
Tested in USA
ACH
Zelle
Research Overview
PT-141 (Bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist derived from Melanotan II. Unlike PDE5 inhibitors that act on the vascular system, PT-141 acts centrally through the melanocortin-4 receptor (MC4R) in the hypothalamus. It received FDA approval in 2019 (Vyleesi®) and represents a mechanistically novel approach in sexual function research.
Mechanism of Action
PT-141 selectively activates the melanocortin-4 receptor (MC4R) in the central nervous system, particularly in hypothalamic regions governing sexual arousal pathways. MC4R activation triggers downstream oxytocin and dopaminergic signaling involved in sexual desire and response. Unlike MT-II, PT-141 has reduced MC1R affinity (minimal pigmentation effect) and a more focused MC4R profile. The central mechanism of action distinguishes it from peripherally-acting compounds.
Experimental Applications
Research includes MC4R signaling characterization, central vs. peripheral sexual arousal pathway studies, hypothalamic neurocircuit mapping, melanocortin receptor selectivity profiling, oxytocin release studies, and comparative pharmacology against MT-II and other MC agonists.
Compound Information
Technical specifications
What is PT-141 (Bremelanotide)?
| Type | Melanocortin Receptor Agonist |
| CAS Number | 189691-06-3 |
| Molecular Weight | 1,025.17 g/mol |
| Amino Acids | 7 |
| Molecular Formula | C₅₀H₆₈N₁₄O₁₀ |
Stability Information
Loading structure…
Estimated plasma concentration over time
Compound Specifications
| Compound Type | Cyclic Heptapeptide (MC4R agonist) |
| Purity | ≥ 99% |
| Appearance | White lyophilized powder |
| Storage | -20°C long-term; 2-8°C short-term |
| Testing Methods | HPLC, Mass Spectrometry |
| Packaging | Sealed sterile vial |
Certificate of Analysis
Lab Testing Notes
Independently tested for purity (?99%) via HPLC and identity via Mass Spectrometry. Cyclic structure integrity confirmed. Full COA available on this product page.
Mechanism of Action
PT-141 selectively activates the melanocortin-4 receptor (MC4R) in the central nervous system, particularly in hypothalamic regions governing sexual arousal pathways. MC4R activation triggers downstream oxytocin and dopaminergic signaling involved in sexual desire and response. Unlike MT-II, PT-141 has reduced MC1R affinity (minimal pigmentation effect) and a more focused MC4R profile. The central mechanism of action distinguishes it from peripherally-acting compounds.
Experimental Applications
Research includes MC4R signaling characterization, central vs. peripheral sexual arousal pathway studies, hypothalamic neurocircuit mapping, melanocortin receptor selectivity profiling, oxytocin release studies, and comparative pharmacology against MT-II and other MC agonists.
Reconstitution Guidelines
Reconstitute with bacteriostatic water. Inject slowly along the inner vial wall. Gently swirl — do not shake. Recommended: 1–2 mL per vial. Store at 2–8°C. Use within 30 days.
How Does PT-141 (Bremelanotide) Compare?
Melanocortin Peptides
| Property | PT-141 (Bremelanotide) | Melanotan II | Melanotan I (Afamelanotide) |
|---|---|---|---|
| Type | Melanocortin Receptor Agonist | Synthetic Peptide (MC receptor agonist) | α-MSH Analog |
| Molecular Weight | 1,025.17 | 1,024.18 | 1,646.85 |
| Amino Acids | 7 | 7 | 13 |
| CAS Number | 189691-06-3 | 121062-08-6 | 75921-69-6 |
| Formula | C₅₀H₆₈N₁₄O₁₀ | C₅₀H₆₉N₁₅O₉ | C₇₈H₁₁₁N₂₁O₁₉ |
| Current | View Product → | View Product → |
Commonly Researched Together
Complementary compounds frequently paired with PT-141 (Bremelanotide) in published studies
Sources & References
Peer-reviewed research
Related Peptides
Premium research peptides, lab-tested for purity
